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Eukaryotic chromosome ends have highly speciali­
zed structures called telomeres, which shorten with 
each cell division and reach to a critical size resulting 
in senescence and eventually cell death [1]. In cancer 
cells, this shortening of telomeres is prevented by a spe­
cial reverse transcriptase enzyme, telomerase. Human 
telomerase is a ribonucleoprotein complex consisting of 
a catalytic subunit (hTERT) and RNA component (hTR), 
and adds telomeric repeats (TTAGGG) to the 3’ ends of 
chromosomes [2, 3]. Telomerase activity is upregulated 
in most carcinomas but not in adjacent normal tissues [4] 
and these cells overcome the limitation of small telomere 
length and entering senescence or apoptosis due to 
genomic instability [5]. In addition hTERT is upregulated 
in 95% of breast carcinomas [6]. Chemotherapeutic 
treatment of breast carcinomas results in acquirement 
of drug resistance by tumor cells. Resistance of tumor 
cells to various cytotoxic drugs is defined as multidrug 
resistance (MDR). Increased drug efflux that results from 
up­regulation of ATP binding cassette (ABC) transporters 
[7, 8], mutations in genes encoding drug target proteins 
[9], differential expressions of drug target proteins and 
anti/proapoptotic proteins [10] are some mechanisms of 
MDR. Although there have been many studies concern­
ing the role of telomerase in cancer, its involvement in 
multidrug resistance remains unclear. Krunaga et al. [11] 
suggested that high telomerase activity and elongation 
of telomeres both appear to help maintain and/or in­
crease drug resistance in colorectal cancer cells. Cancer 
cells with long telomeres and a high proliferative activity 
may thus be able to survive upon exposure to anti­cancer 
drugs. Cereno et al. [6] showed that telomerase inhibi­
tion enhances response to anticancer drug treatment in 
breast cancer however they have also concluded that 
presence of shorter telomeres may impair the ability of 
cells to recover from drug treatment.
The aim of the present study is to investigate a pos­
sible correlation between MDR and telomerase in 
paclitaxel (MCF­7/Pac), docetaxel (MCF­7/Doc), vin­
cristine (MCF­7/Vinc) and doxorubicin (MCF­7/Dox) 
resistant MCF­7 cells. For this purpose, the expres­
sion levels of the catalytic component of telomerase 
(hTERT) and telomerase activity in sensitive MCF­7 and 
drug resistant sublines were determined.
MATERIALS AND METHODS
Cell lines. Drug resistant MCF­7 cell lines, which 
were models for drug resistant human mammary carci­
noma, were developed in the laboratory. The features and 
growth conditions of the parental and resistant sublines 
were described previously by Kars et al [12]. The sublines 
resistant to 400 nM paclitaxel (MCF­7/Pac), 120 nM do­
cetaxel (MCF­7/Doc), 120 nM vincristine (MCF­7/Vinc) 
and 1000 nM doxorubicin (MCF­7/Dox) were used to test 
the antiproliferative effects of anticancer agents. 
Assay for cell proliferation. Antiproliferative 
effects of anticancer drugs (paclitaxel, docetaxel, 
vincristine and doxorubicin) on sensitive and resistant 
cell lines were determined by means of a XTT based 
Cell Proliferation Kit (Biological Industries, Israel). IC50 
values were found from percent cell proliferation versus 
log (anticancer drug concentration) curves and resis­
tance indices of developed cell lines were evaluated as 
previously described [13]. 
RNA isolation and reverse transcription-poly-
merase chain reaction (RT-PCR). RNA isolation was 
performed according to guanidium thiocyanide/phenol­
chloroform single­step RNA isolation method [14]. 
cDNA synthesis reaction was performed with 5 µg of 
total RNA and cDNA was used as template for PCR reac­
tions. PCR conditions for hTERT and internal standard 
beta2- microglobulin (β2-m) was previously described 
[2, 12]. PCR products were examined by native agarose 
(2% w/v) gel electrophoresis and visualized by ethidium 
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bromide staining. Densitometric measurements of band 
intensities were performed using Scion Image Software 
(Scion Corporation, Maryland, USA).
Assay for telomerase activity. TRAPeze® telomerase 
detection kit (Chemicon, MA, USA) was used according 
to manufacturer’s instructions with modifications to as­
sess telomerase activity of sensitive and resistant MCF­7 
cells. In brief, 1 x 105 cells were resuspended in 200 µL of 
ice­cold CHAPS lysis buffer and incubated for 30 min on 
ice. After centrifugation of lysate at 12,000 x g for 30 min 
at 4 °C, the resulting supernatant was stored at –80 °C. 
The protein concentration of each extract was determined 
with Bradford assay [15]. Two microliters of diluted ex­
tract (200 ng/µL) was added to 48 µL of reaction mixture 
containing 10X TRAP buffer (5 µL), 50X deoxynucleotide 
triphosphates mix (1 µL), TS primer (1 µL), TRAP primer 
mix (1 µL), 5 units/µL Taq polymerase (0.4 µL), and distilled 
H20 (39.6 µL). Each analysis included a positive control 
obtained from telomerase positive cell extract (provided 
with the kit) and a negative control containg CHAPS lysis 
buffer. The tubes were incubated in thermocycler at 30 ˚ C 
for 30 min for the elongation of TS primer by telomerase 
and followed by 33 cycles of PCR amplification (94 °C 
for 30 s, 59 °C for 30 s and 72 °C for 60 s). The products 
were examined on non­denaturing polyacrylamide gel 
(10% w/v) and visualized by a silver staining. A sample 
was considered as positive for telomerase activity when 
characteristic ladder of TRAP products (TP) with 6 bp in­
crements and a 36­bp internal control (IC) were observed 
and negative when only internal control was present. 
Densitometric analysis of the gels was carried out by Im­
age J Software and relative telomerase activity (RTA) was 
calculated by the following formula: 
 (XTP/XIC)RTA = ——————, (Equation 1)
 (TelTP/TelIC)
where densitometric band intensities were designated 
by X and Tel for the samples and telomerase positive 
control, respectively. 
Statistical analysis. The results of RT­PCR and 
RTA were subjected to two­tailed t­test by using SPSS 
Software (SPSS Inc., Illinois, USA) to determine signifi­
cant difference between means of groups (α = 0.05). 
RESULTS
Determination of drug resistance. According to 
results of cell proliferation assays (Fig. 1), developed 
sublines were acquired resistance to their selective 
drugs. Calculated IC50 values of sensitive and resistant 
cells were significantly different and the resistance 
indices showed that MCF­7/Pac, MCF­7/Doc, MCF­7/
Vinc and MCF­7/Dox cells were 150­, 47­, 30­ and 
160­folds resistant to these drugs, respectively com­
pared to the original sensitive MCF­7 cells.
RT-PCR. RT­PCR results demonstrated that sensi­
tive and all resistant cells had intrinsic expression of 
hTERT (Fig. 2, a). According to band intensity ratios 
(hTERT/β2-m), difference in hTERT expression le vels 
of sensitive and resistant cell lines was not found sta­
tistically significant (Fig. 2, b).
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Fig. 1. Effects of anticancer drugs on sensitive and resistant MCF­7 
cell lines. Mean IC50 and standard error of the means (SEM) were 
derived from three independent experiments
*, **, ***, ****marks on bars represent significant differences be­
tween MCF­7,Doc(+)­MCF­7/Doc,Doc(+); MCF­7,Pac(+)­MCF­7/
Pac,Pac(+); MCF­7,Vinc(+)­MCF­7/Vinc,Vinc(+) ; MCF­7,Dox(+)­
MCF­7/Dox,Dox(+) pairs, respectively (p < 0.05). 
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Fig. 2. RT­PCR results: a — hTERT and 122 bp β microglobulin RT­PCR 
products on 2% agarose gel, b — Relative hTERT expression levels. 
Mean ratios and SEM were derived from two independent experiments
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Fig. 3. TRAP assay: a — TRAP products on 10% polyacrylamide gel; 
b — illustration of RTA levels in sensitive and resistant cell lines. Mean 
RTA and SEM were derived from two independent experiments
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Telomerase activity. As it was determined by 
TRAP — Silver Staining assay it was clear that all of 
the cell lines showed telomerase activity regardless of 
their resistance (Fig. 3, a). There was no statistically 
significant difference in telomerase activity levels of 
sensitive and drug resistant cell lines (Fig. 3, b).
DISCUSSION
Human tumors develop resistance to chemothera­
peutic drugs with an approximate outcome of 40% [16] 
and overcoming this phenomenon requires the under­
standing of the resistance mechanisms. Even though 
some molecular mechanism of multidrug resistance is 
well known, the idea that telomerase might be involved in 
this process is under investigation. Hoos et al. [17] previ­
ously showed that telomerase activity was decreased in 
all chemotherapy­treated tumors compared to untreated 
tumors in breast cancer patients. In concordance, telom­
erase activity was shown to decline in tumor cell cultures 
after treatment with antineoplastic agents [18]. In this 
study, the expression levels of the catalytic component 
of telomerase enzyme, hTERT, and telomerase activity 
were investigated in paclitaxel, docetaxel, vincristine and 
doxorubicin resistant MCF­7 sublines and their sensitive 
parental line. Proliferation assays confirmed develop­
ment of resistance to these drugs in selected cells. These 
sublines also overexpressed resistance related MDR1 
gene (data not shown). According to RT­PCR results, 
there were no significant differences in mRNA levels of 
hTERT in sensitive and resistant MCF­7 cells. Similarly, 
study of telomerase activities did not demonstrate sig­
nificant differences in relative levels of resistant MCF­7 
sublines when compared to sensitive MCF­7 cells. In 
conclusion, the data provided here suggest that drug 
resistance developed against paclitaxel, docetaxel, vin­
cristine and doxorubicin in MCF­7 cells does not seem to 
have direct association with expression levels of hTERT 
and telomerase activity levels. 
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ЭКСПРЕССИЯ ГЕНА hTERT И ТЕЛОМЕРАЗНАЯ АКТИВНОСТЬ 
В КЛЕТКАХ MCF-7, ОБЛАДАЮЩИХ ЛЕКАРСТВЕННОЙ 
РЕЗИСТЕНТНОСТЬЮ
В опухолевых клетках, а также некоторых нормальных клетках с высоким пролиферативным потенциалом длина теломеров 
может стабилизироваться за счет фермента теломеразы, добавляющего гексамерные повторы к концам линейных хромо-
сом. Цель: проанализировать активность обратной транскриптазы теломеразного комплекса и экспрессию гена теломеразы 
в клетках MCF-7 аденокарциномы молочной железы человека, устойчивых к паклитакселу, доцетакселу, винкристину и 
доксорубицину. Материалы и методы: сублинии клеток MCF-7, обладающих лекарственной резистентностью, были полу-
чены путем селекции исходных клеток при культивировании их в присутствии возрастающих доз паклитаксела (MCF-7/Pac), 
доцетаксела (MCF-7/Doc), винкристина (MCF-7/Vinc) и доксорубицина (MCF-7/Dox). Антипролиферативный эффект 
противоопухолевых препаратов определяли в ХТТ-тесте. Величины IC50 для различных препаратов определяли по кривым 
пролиферации клеток. Уровень экспрессии гена hTERT в чувствительных и резистентных клетках анализировали методом 
ОТ-ПЦР. Теломеразную активность определяли с помощью набора TRAPeze. Результаты: проанализированные резистентные 
линии клеток MCF-7 не отличались от исходной линии ни по уровню экспрессии гена hTERT, ни по уровню теломеразной 
активности. Выводы: развитие лекарственной резистентности к паклитакселу, доцетакселу, винкристину и доксорубицину 
в клетках MCF-7 не связано с изменениями экпрессии гена hTERT или уровня теломеразной активности в них.
Ключевые слова: hTERT, теомеразная активность, лекарственная резистентность, MCF-7.
